The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. IRLAB Therapeutics AB's Revenue for the
three
months ended in Mar. 2026 was kr39.36 Mil. IRLAB Therapeutics AB's average Accounts Receivable for the
three
months ended in Mar. 2026 was kr32.95 Mil.
Hence, IRLAB Therapeutics AB's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.19.
IRLAB Therapeutics AB (OSTO:IRLAB A) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
IRLAB Therapeutics AB Receivables Turnover Related Terms
IRLAB Therapeutics AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for IRLAB Therapeutics AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:IRLAB A vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, IRLAB Therapeutics AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IRLAB Therapeutics AB Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where IRLAB Therapeutics AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IRLAB Therapeutics AB (OSTO:IRLAB A) has a Receivables Turnover of 1.19 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on IRLAB Therapeutics AB and its competitors. According to the industry distribution chart, IRLAB Therapeutics AB ranks #380 out of 841 companies in the Biotechnology industry, placing it in the top 45.2%.
Is IRLAB Therapeutics AB's Receivables Turnover too high?
IRLAB Therapeutics AB's current Receivables Turnover is 1.19. The Biotechnology industry median Receivables Turnover is 5.29. IRLAB Therapeutics AB's value of 1.19 is 77.5% below this industry median. Based on the distribution chart, IRLAB Therapeutics AB ranks #380 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, IRLAB Therapeutics AB has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRLAB Therapeutics AB's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, IRLAB Therapeutics AB ranks #380 out of 841 companies for Receivables Turnover. This puts IRLAB Therapeutics AB in the upper half of its industry. The industry median Receivables Turnover is 5.29. IRLAB Therapeutics AB's value of 1.19 is 77.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IRLAB Therapeutics AB's current Receivables Turnover of 1.19 is 77.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on IRLAB Therapeutics AB and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IRLAB Therapeutics AB's current Receivables Turnover is 1.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRLAB Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, IRLAB Therapeutics AB (OSTO:IRLAB A) is currently considered Possible Value Trap. The stock's GF Value™ is kr11.73, compared to a current price of kr1.40 — trading 88.1% below its estimated fair value. The current Receivables Turnover is 1.19 and 77.5% below the Biotechnology industry median of 5.29. IRLAB Therapeutics AB's overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For IRLAB Therapeutics AB (OSTO:IRLAB A), the current Receivables Turnover is 1.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?
Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued.
The current stock price of kr1.40 is trading 88.1% below its estimated GF Value™ of kr11.73.
GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.
Key valuation signals for OSTO:IRLAB A:
Receivables Turnover: 1.19
GF Value™: kr11.73 vs. price of kr1.40 (88.1% below fair value)
Industry Position: 77.5% below the Biotechnology median (#380 of 841)
No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
35GF Score
Get the complete analysis for OSTO:IRLAB A
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:IRLAB A has been successfully added to your 
